GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
Source | Last Updated |
---|---|
GlycoNAVI Proteins | November 28, 2024 |
PDB ID ▼ | UniProt ID | Title | Descriptor |
---|---|---|---|
8H14 | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x3 Disulfide (D414C and V969C), Locked-1 Conformation | |
8H13 | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x2 Disulfide (G400C and V969C), Closed Conformation | |
8H12 | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x2 Disulfide (G400C and V969C), Locked-2 Conformation | |
8H11 | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Closed Conformation | |
8H10 | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-2 Conformation | |
8H0Z | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-122 Conformation | |
8H0Y | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-112 Conformation | |
8H0X | P59594 | Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-1 Conformation | |
8H08 | P0DTC2 | SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H08 | 8H08 | SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H08 | P0DTC2 | SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H08 | 8H08 | SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H07 | P0DTC2 | SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H07 | 8H07 | SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H07 | P0DTC2 | SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H07 | 8H07 | SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C | |
8H06 | Q9BYF1 | Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement) | |
8H06 | P0DTC2 | Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement) | |
8H01 | P0DTC2 | SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in class 2 conformation | |
8H01 | 8H01 | SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in class 2 conformation | |
8H00 | P0DTC2 | SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in the class 1 conformation | |
8H00 | 8H00 | SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in the class 1 conformation | |
8GZ5 | P0DTC2 | Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-binding domain | |
8GZ5 | 8GZ5 | Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-binding domain | |
8GZ3 | P13498 | Structure of human phagocyte NADPH oxidase in the resting state | |
8GZ3 | P04839 | Structure of human phagocyte NADPH oxidase in the resting state | |
8GZ3 | 8GZ3 | Structure of human phagocyte NADPH oxidase in the resting state | |
8GZ2 | Q9UQD0 | Cryo-EM structure of human NaV1.6/beta1/beta2-4,9-anhydro-tetrodotoxin | |
8GZ2 | O60939 | Cryo-EM structure of human NaV1.6/beta1/beta2-4,9-anhydro-tetrodotoxin | |
8GZ2 | Q07699 | Cryo-EM structure of human NaV1.6/beta1/beta2-4,9-anhydro-tetrodotoxin | |
8GZ1 | Q9UQD0 | Cryo-EM structure of human NaV1.6/beta1/beta2,apo state | |
8GZ1 | O60939 | Cryo-EM structure of human NaV1.6/beta1/beta2,apo state | |
8GZ1 | Q07699 | Cryo-EM structure of human NaV1.6/beta1/beta2,apo state | |
8GYY | G8GLP2 | Bifunctional xylosidase/glucosidase LXYL with intermediate substrate xylose, 120 seconds | |
8GYT | Q96QZ0 | Cryo-EM structure of human Pannexin-3 R36S/F40R variant in pre-open state. | |
8GYQ | Q96RD6 | Cryo-EM structure of human Pannexin-2 in pre-open state. | |
8GYP | Q96QZ0 | Cryo-EM structure of human Pannexin-3 in closed state. | |
8GYO | Q96RD7 | Inner channel lipids regulated gating mechanism of human pannexins. | |
8GYE | Q07011 | Crystal Structure of the 4-1BB in complex with ZG033 Fab | |
8GYE | 8GYE | Crystal Structure of the 4-1BB in complex with ZG033 Fab | |
8GX9 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 | |
8GX9 | 8GX9 | Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 | |
8GVM | P00396 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P68530 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P00415 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P00423 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P00426 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P00428 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P07471 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days | |
8GVM | P00429 | The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024